Company: SUPN
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001356576-25-000071
Chunk: 303

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 2
Chunk 303
---
 current liabilities in Accrued product returns and rebates, on our condensed consolidated balance sheets. We record sales discounts as a reduction against Accounts receivable, net on the unaudited condensed consolidated balance sheets. Both amounts are generally affected by changes in gross product sales, changes in the provision for net product sales deductions, and the timing of payments/credits.

The following table provides a summary of activity with respect to accrued product returns and rebates and sales discounts during the periods indicated (dollars in thousands): Accrued Product Returns and RebatesProductReturnsProductRebatesSales DiscountsTotalBalance at December 31, 2024$53,375 $115,330 $12,347 $181,052 Provision related to:Current year sales9,672 295,476 51,015 356,163 Prior year sales(16,312)(330)40 (16,602)Total provision(6,640)295,146 51,055 339,561 Less: Actual payments/credits(3,466)(269,286)(45,098)(317,850)Balance at September 30, 2025$43,269 $141,190 $18,304 $202,763 

Accrued Product Returns and RebatesProductReturnsProductRebatesSales DiscountsTotalBalance at December 31, 2023$57,290 $96,984 $10,719 $164,993 Provision related to:Current year sales15,615 295,831 52,372 363,818 Prior year sales(7,345)(2,244)(6)(9,595)Total provision8,270 293,587 52,366 354,223 Less: Actual payments/credits(8,131)(278,876)(52,097)(339,104)Balance at September 30, 2024$57,429 $111,695 $10,988 $180,112 

Accrued Product Returns and Rebates

The accrued product returns balance decreased to $43.3 million as of September 30, 2025 from $57.4 million as of September 30, 2024. This decrease was primarily due to the $16.3 million of estimated provision for product returns related to prior year sales. The majority of the provision for product returns related to prior year sales is attributable to Qel